Treatment of Parkinson’s disease with subcutaneous lisuride infusions
Four patients with Parkinson’s disease and severe fluctuating responses to levodopa and oral dopamine agonists were treated with continuous administration of lisuride infusions, administered by means of an externally worn pump.
Levodopa dosage ranged from 300 to 687mg/day and was kept stable throughout the study.
In addition increasing doses of lisuride were injected subcutaneously in the abdomen.
Lisuride doses ranged from 41 to 104µg/h.
A marked improvement in mobility was observed in every patient while severe biphasic dyskinesais almost remitted in one of them.
The most common side-effect was the presence of subcutaneous nodules appearing at the injection site.
Two cases had mild hemorrhagic complications and one initially had nausea. One patient developed acute psychiatric disturbances severe enough to be excluded from the study.
Our findings suggest that lisuride subcutaneous infusions can be useful in severily handicapped parkinsonian patients, however local and psychiatric side- effects may be a serious threat in the long-term care.
KeywordsDisability Score Parkinsonian Patient Mini Mental Status Examination Score Subcutaneous Nodule Levodopa Dosage
Unable to display preview. Download preview PDF.
- Barbeau A (1975) Long-term side effects of levodopa. Lancet 1: 395Google Scholar
- Barbeau A (1974) The physiology of side-effects in long term L-dopa therapy. In: Me Dowell F, Barbeau A (eds) Advances in neurology, vol 5. Raven Press, New York, pp 347–365Google Scholar
- Calne DB, Claveria LE, Allen J (1974) Plasma levodopa and the “On-Off” effect. In: McDowell F, Barbeau A (eds) Advances in neurology, vol 5. Raven Press, New York, pp 366–384Google Scholar
- Castro-Caldas A, Costa Cristina, Sampaio Cristina (1986) Lisuride infusion pump for Parkinson’s disease (Letter). Lancet 1: 1150-1151 Cotzias GC, van Woert HH, Schiffer LM (1967) Aromatic aminoacids and modification of parkinsonism. N Engl J Med 276: 374–379Google Scholar
- Garcia de Yébenes J, Avila C, Bazán E, Gervás J, Maseda C, Mena MA, Muradas V, Ramos J A (1982) Aspectos farmacocineticos y farmacodinámicos del tratamiento con L-dopa, más inhibidor de la dopa decarboxilasa y agonistas dopaminérgicos en la enfermedad de Parkinson. Med Clin 78: 259–264Google Scholar
- Glough CG (1982) “On-Off” syndrome in Parksinon’s disease and intravenous levodopa. Lancet 2: 765Google Scholar
- Marsden CD, Parkes JD (1976) “On-Off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1: 292–296Google Scholar
- Marsden CD (1977) The need for an alternative therapy in Parkinson’s disease. In: Lakke JPWF, Karf J, Wesseling H (eds) Parkinson’s disease. Concepts and prospects. Excerpta Medica, Amsterdam, pp 117–120Google Scholar
- Marsden CD, Parkes JD, Quinn N (1982) Fluctuations of disability in Parkinson’s disease. Clinical Aspects. In: Marsden CD, Fahn S (eds) Movements disorders. Butterworth, London, pp 92–122Google Scholar
- Obeso JA, Luquin MR, Martinez-Lage JM (1983 a) Lisuride infusion for Parkinson’s disease. Ann Neurol 14: 134Google Scholar
- Obeso JA, Martinez-Lage JM, Luquin MR, Bolio N (1983 b) Intravenous lisuride infusions for Parkinson’s disease. Ann Neurol 14: 252Google Scholar
- Quinn N, Parkes JD, Marsden CD (1984) Control “On-Off” phenomenon by continuous intravenous infusion of levodopa. Neurology 34: 1131-1136 Shoulson I, Glaubiger GA, Chase TN (1975) “On-Off” response clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25: 1144–1148Google Scholar